Arslan Mustafa
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Amasya University, Turkey.
J Arthropod Borne Dis. 2024 Sep 30;18(3):276-280. doi: 10.18502/jad.v18i3.18578. eCollection 2024 Sep.
Crimean-Congo hemorrhagic fever (CCHF) is a viral zoonotic disease characterized by high fever, bleeding manifestations, and a high mortality rate. Most patients begin to experience bleeding 5 to 7 days after the onset of the illness, usually while hospitalized. This report highlights that even though patients may develop shock and multi-organ failure, there might be no visible signs of bleeding until shortly before death.
This case report describes a 42-year-old male patient with a confirmed diagnosis of CCHF via RT-PCR, who died despite intensive care treatment. Despite receiving intensive care treatment, he did not respond to the septic shock therapy and unfortunately passed away within a few hours. The diagnosis of the disease was made by the reference laboratory with a positive reverse transcriptase-polymerase chain reaction (RT-PCR) test for CCHF.
In this case, the patient exhibited no visible signs of bleeding, such as hematemesis, melena, or gross hematuria, despite being in shock. While CCHF mortality (5-30%) typically occurs during the 3-5-day hemorrhagic phase, this patient died suddenly due to massive intra-abdominal bleeding, skipping the typical bleeding phase.
Clinicians should consider that individual differences may be seen in the clinical course of CCHF disease. In addition, the Coronavirus Disease-2019 (COVID-19) pandemic was experienced worldwide when the patient applied. Given the overlapping initial symptoms of COVID-19 and CCHF, clinicians should prioritize differential diagnosis, especially during the COVID-19 pandemic. During the COVID-19 pandemic, diagnostic delays may occur in the management of CCHF, particularly due to resource allocation.
克里米亚-刚果出血热(CCHF)是一种病毒性人畜共患病,其特征为高热、出血表现和高死亡率。大多数患者在发病后5至7天开始出现出血症状,通常是在住院期间。本报告强调,尽管患者可能会发展为休克和多器官功能衰竭,但在临死前不久才可能出现明显的出血迹象。
本病例报告描述了一名42岁男性患者,经逆转录聚合酶链反应(RT-PCR)确诊为CCHF,尽管接受了重症监护治疗仍死亡。尽管接受了重症监护治疗,但他对感染性休克治疗无反应,不幸在数小时内去世。该疾病的诊断由参考实验室通过对CCHF的逆转录酶-聚合酶链反应(RT-PCR)检测呈阳性做出。
在本病例中,尽管患者处于休克状态,但未出现明显的出血迹象,如呕血、黑便或肉眼血尿。虽然CCHF的死亡率(5%-30%)通常发生在3至5天的出血期,但该患者因腹腔内大量出血突然死亡,跳过了典型的出血期。
临床医生应考虑到CCHF疾病的临床过程可能存在个体差异。此外,患者就诊时全球正经历2019冠状病毒病(COVID-19)大流行。鉴于COVID-19和CCHF最初症状重叠,临床医生应优先进行鉴别诊断,尤其是在COVID-19大流行期间。在COVID-19大流行期间,CCHF的管理可能会出现诊断延迟,特别是由于资源分配问题。